SLAC National Accelerator Laboratory

SLAC joins the global fight against COVID-19

The lab is responding to the coronavirus crisis by imaging disease-related biomolecules, developing standards for reliable coronavirus testing and enabling other essential research.

Newswise — As part of the international response to the COVID-19 pandemic, the U.S. Department of Energy’s SLAC National Accelerator Laboratory has re-opened some of its facilities for essential research on the atomic structure of the virus and how it interacts with potential treatments and vaccines.

SLAC scientists are also leading the development of global standards to ensure reliable testing for the coronavirus and participating in DOE working groups that are considering a wide range of proposals for coronavirus research, including high-throughput drug screening and novel approaches for building ventilators.

“Working with our fellow national labs, Stanford University and other partners, we’re applying our unique expertise and facilities to make a difference in the global fight against this disease,” said SLAC Director Chi-Chang Kao. 

Targeting the virus on an atomic level

At the forefront of SLAC’s coronavirus research are techniques that use beams of X-rays or electrons to decipher how life’s molecular machinery works on the atomic level. This can help answer key questions about SARS-CoV-2, the virus that causes COVID-19, such as how it recognizes and infects cells, how it replicates within them, and how it spreads through our bodies. This detailed knowledge can feed into the development of vaccines and treatments with drugs or antibodies.

While the March 16 San Francisco Bay Area’s shelter-in-place order temporarily shut down all but essential operations at the lab, the Stanford Synchrotron Radiation Lightsource (SSRL) is operating a subset of its experimental stations to provide powerful X-rays for coronavirus-related studies.

One method they are using is X-ray crystallography, which examines biomolecules such as the spike proteins on the surface of SARS-CoV-2. These proteins dock onto receptor molecules on the surface of cells in the lungs, heart or intestines and spill the virus’s genetic material into the host cells where it replicates.

Researchers crystallize these biomolecules for analysis with SSRL’s X-rays, which produces detailed images of where each atom of the protein is located. These 3D maps can then feed into the design of targeted therapeutic interventions, for instance drugs that block spike proteins from binding to host cells.

Collaborating with researchers from other institutions, the SSRL team is working to determine the 3D structures of a number of biomolecules involved in the life cycle of SARS-CoV-2.

“We’re able to do this research and, at the same time, follow strict social distancing protocols because our experimental stations are highly automated and require only minimal staff on site,” said Aina Cohen, who co-leads SSRL’s Structural Molecular Biology Division. “Researchers can send us frozen samples to be mounted by robots into the experimental stations. The remote researchers then use our software and video tools to control the robots, view their samples, and control all the details of their experiment from their home lab, or even from their homes.”

Another method used at SSRL is small-angle X-ray scattering, which looks at how X-rays bounce off biomolecules and their complexes in solution. Thomas Weiss, who oversees the research at this experimental station, is collaborating with Gerard Wong’s lab and other scientists at the University of California, Los Angeles, as well as researchers at the University of California, San Diego, to look at how pieces of viral proteins interact with the machinery of the human immune system. Insights into these interactions could help scientists understand why SARS-CoV-2 is so infectious and causes so much inflammation – a principal reason for why it is so deadly.

In parallel, researchers at two National Institutes of Health (NIH) centers – the Stanford-SLAC Cryo-EM Center and the National Center for Macromolecular Imaging – are pursuing answers to very similar questions with cryogenic electron microscopy (cryo-EM), which uses electron beams to study the novel coronavirus and how its molecular components interact with drugs or antibodies. One advantage of this technique is that it produces atomic-resolution images of biomolecules in their frozen, hydrated state, with no need for crystallization. 

“One of the projects in full swing is a collaboration with Professor Rhiju Das at the Stanford Medical School that is aimed at designing a drug to keep viral RNA from carrying out its normal function,” said Wah Chiu, director of the NIH centers. This work involves developing synthetic RNA molecules that mimic stretches of the viral RNA, determining their 3D structures with cryo-EM and using that information to build molecules that can bind and deactivate the RNA.

In addition, Chiu and his colleagues have teamed up with several groups around the world that are preparing virus-like particles, viral proteins and RNA-protein complexes for cryo-EM analysis, as well as virus-infected cells for tomographic studies of what exactly the virus does once it enters host cells.

SLAC is also planning to bring experimental stations at its Linac Coherent Light Source (LCLS) back on line for COVID-19-related research. One of the brightest X-ray sources on Earth, this X-ray laser will complement other techniques ­– looking, for example, at hard-to-crystallize viral particles at room temperature to see how the virus attacks host cells and interacts with potential drugs under conditions that are close to those in the human body.

Toward reliable coronavirus testing

Another important area is making sure that tests for coronavirus are reliable, no matter when or where they take place. Defining standards that guarantee just that is the focus of an initiative launched by SLAC’s Marc Salit, director of the Joint Initiative for Metrology in Biology (JIMB).

“My team has been developing a Coronavirus Standards Working Group as the authoritative body to catalog existing standards and studies that will give us a global COVID-19 testing enterprise we can trust, and also fill in any gaps we find,” Salit said. “The idea is to create something enduring, institutionalized and poised for the next time so we can ensure we have the tools available to underpin the development of reliable testing.”

Although the working group is only a few weeks old, it has already become an active research community, bringing together leaders from government, academia, professional societies, international standards bodies, technology developers and the makers of standards and controls. The group is scoping standards for virus and antibody testing and exploring the creation of an open repository of clinical samples to support more test development and research.

A community-wide response

SLAC is also part of DOE’s COVID-19 working group, which brings together all 17 national labs in a coordinated response to explore the broad range of advanced scientific tools, deep technological knowledge and unique expertise the labs can bring to the table. This system-wide effort is developing ideas and approaches in a number of areas, including bioimaging, therapeutics, computing, materials and supply chains.

“SLAC is participating vigorously in all of these areas, leveraging our expertise in fabrication, electronics, prototyping, metrology and more,” said Steve Eglash, director of SLAC’s Applied Energy Division.

SLAC and Stanford faculty member Yi Cui, for example, has teamed up with Stanford colleague Steven Chu and Silicon Valley start-up 4C Air for a study that uses heat to sterilize N95 face masks that protect health care workers from COVID-19. The masks are in short supply, and disinfection could allow front-line medical workers to safely reuse them.

Other areas where SLAC’s expertise and tools could be used are the 3D printing of masks, the design of new, simplified types of ventilators, and the long-distance control of these devices, which would allow adjusting them without coming close to infectious patients. Members of SLAC’s machine learning initiative are also looking into how their computational methods can help with the analysis of complex cryo-EM and tomographic data.

“We’re seeing a lot of enthusiasm from many people all around the lab,” Eglash said. “Our community is really coming together and has already produced a long list of promising ideas to explore. The weeks and months ahead will tell us which of these projects will move ahead.”

Part of this work is funded by the DOE Office of Science. SSRL and LCLS are DOE Office of Science user facilities. Experimental stations for X-ray crystallography and X-ray scattering are part of the SSRL Structural Molecular Biology Program, which is supported by the DOE Office of Biological and Environmental Research and by the NIH, National Institute of General Medical Sciences. The Cryo-EM centers are funded by the NIH Common Fund Transformative High Resolution Cryo-Electron Microscopy program and National Institute of General Medical Sciences Biomedical Technology Research Resource Program. JIMB is hosted by SLAC in collaboration with the National Institute of Standards and Technology (NIST) and Stanford.

SLAC is a vibrant multiprogram laboratory that explores how the universe works at the biggest, smallest and fastest scales and invents powerful tools used by scientists around the globe. With research spanning particle physics, astrophysics and cosmology, materials, chemistry, bio- and energy sciences and scientific computing, we help solve real-world problems and advance the interests of the nation.

SLAC is operated by Stanford University for the U.S. Department of Energy’s Office of Science. The Office of Science is the single largest supporter of basic research in the physical sciences in the United States and is working to address some of the most pressing challenges of our time.



Filters close

Showing results

110 of 5809
Newswise: 267646_web.jpg
Released: 11-Jun-2021 2:10 PM EDT
Saliva can be more effective than nasopharyngeal swabs for COVID-19 testing
Elsevier

The collection of nasopharyngeal swab (NPS) samples for COVID-19 diagnostic testing poses challenges including exposure risk to healthcare workers and supply chain constraints.

Released: 11-Jun-2021 1:25 PM EDT
Physical Activity May Curb Health Care Worker Burnout
University of Georgia

More physical activity programming could mitigate the effects of stress and improve worker mental and emotional health.

Newswise: AI Predicts How Patients with Viral Infections, Including COVID-19, Will Fare
9-Jun-2021 6:05 PM EDT
AI Predicts How Patients with Viral Infections, Including COVID-19, Will Fare
University of California San Diego Health

UC San Diego School of Medicine researchers discovered gene expression patterns associated with pandemic viral infections, providing a map to help define patients’ immune responses, measure disease severity, predict outcomes and test therapies — for current and future pandemics.

Released: 10-Jun-2021 5:35 PM EDT
Senolíticos reducen síntomas de COVID-19 en estudios preclínicos
Mayo Clinic

Los investigadores de Mayo Clinic y sus colegas de la Universidad de Minnesota demostraron que la COVID-19 exacerba las consecuencias nocivas de las células senescentes en el cuerpo. En estudios preclínicos, los fármacos senolíticos descubiertos en Mayo redujeron considerablemente la inflamación, la enfermedad y la mortalidad debida a la infección por covid en ratones ancianos. Los resultados se publican en la revista Science.

Released: 10-Jun-2021 5:30 PM EDT
Senolíticos reduzem os sintomas de COVID-19 em estudos pré-clínicos
Mayo Clinic

Os pesquisadores da Mayo Clinic e colegas da Universidade de Minnesota mostraram que o COVID-19 intensifica o impacto prejudicial das células senescentes no corpo. Em estudos pré-clínicos, os medicamentos senolíticos descobertos na Mayo reduziram significativamente a inflamação, a gravidade da doença e a mortalidade da infecção por COVID em camundongos mais velhos. Essas conclusões foram publicadas na revista Science.

Newswise: FresnoSTateVaxImage2.jpg
Released: 10-Jun-2021 5:25 PM EDT
CSU Campuses Join COVID-19 College Vaccine Challenge
California State University (CSU) Chancellor's Office

The CSU pledges to be a Vaccine Champion University as part of new White House effort aimed at increasing vaccinations for younger Americans.

Released: 10-Jun-2021 5:05 PM EDT
الأدوية المحللة للشيخوخة تقلل من أعراض فيروس كورونا المستجد (كوفيد-19) في الدراسات ما قبل السريرية
Mayo Clinic

أظهر باحثو مايو كلينك وزملاؤهم في جامعة مينيسوتا أن فيروس كورونا المستجد (كوفيد-19) يفاقم التأثير الضار للخلايا الشائخة في الجسم. ففي الدراسات ما قبل السريرية، قللت الأدوية المحللة لالشيخوخة التي تم اكتشافها في مايو بشكل كبير من الالتهاب والمرض والوفيات الناجمة عن عَدوى فيروس كورونا المستجد في الفئران الأكبر سنًا. النتائج منشورة في مجلة ساينس.

7-Jun-2021 7:05 AM EDT
Study Examines the Effects of COVID-19 on Human Kidney Cells
American Society of Nephrology (ASN)

• The virus that causes COVID-19 can infect and replicate in human kidney cells, but this does not typically lead to cell death. • Kidney cells that already have features of injury may be more easily infected and develop additional injury.

Released: 10-Jun-2021 4:55 PM EDT
抗衰老药物在临床前研究中减少COVID-19症状。
Mayo Clinic

妙佑医疗国际(Mayo Clinic)的研究人员和明尼苏达大学的同事表明,COVID-19(2019冠状病毒病)加剧了体内衰老细胞的破坏性影响。在临床前研究中,妙佑医疗国际研发的抗衰老药物显著降低了老年实验鼠因COVID(冠状病毒病)感染引起的炎症、疾病和死亡率。该研究结果已发表在《科学》期刊中。

Newswise: blobid0_1623274320110.jpg
Released: 10-Jun-2021 4:45 PM EDT
How does COVID-19 affect patients with cancer? Largest U.S. study shares first results
University of Alabama at Birmingham

New findings include a significant increase in risk of death among patients who had recently had chemotherapy.


Showing results

110 of 5809

close
1.21264